Eli Lilly Launches Daily Foundayo Pill in UK, Europe’s First Approval for GLP-1 Tablet
Updated
Updated · The Guardian · Aug 24
Eli Lilly Launches Daily Foundayo Pill in UK, Europe’s First Approval for GLP-1 Tablet
3 articles · Updated · The Guardian · Aug 24
Summary
Monday marks the UK pharmacy launch of Eli Lilly’s Foundayo, a once-daily pill for weight loss and type 2 diabetes that is initially available only by private prescription.
MHRA authorized orforglipron earlier this month, making the UK the first European market to offer the drug; it can be taken any time of day without food or water restrictions.
BMI thresholds limit use to patients with obesity or overweight plus a related condition, while the pill is also licensed to improve blood sugar control in poorly controlled type 2 diabetes.
Pharmacists said the tablet could widen access for patients who cannot or do not want injections, but warned that counterfeit and unlicensed GLP-1 pills may be easier to produce and sell.
NHS access is still pending a NICE assessment, leaving campaigners to press for broader pharmacy-based rollout instead of what they called a postcode lottery in weight-management services.
While the UK pioneers Europe's first non-restrictive GLP-1 tablet, will its initial private prescription status silently widen the health inequality gap?
With a new daily weight-loss pill eliminating injections, could this unprecedented convenience trigger an unstoppable wave of dangerous counterfeit drugs?
Can this highly anticipated daily tablet conquer injection phobia, or will severe gastrointestinal side effects force desperate patients to abandon treatment?